Merck + Co., Inc.

Jacobus Pharmaceutical Company, Inc.

Norman P Jensen

Michael N Chang

David Penman Jacobus

Milton L Hammond

Robert A Zambias

John McDonald

Kathleen M Rupprecht

Hong-Ming Shieh

Jacek Terpinski

Howard Jones

Tsung-Ying Shen

Arthur F Wagner

David P Jacobus

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Biguanide and dihydrotriazine derivatives

Antimalarial N,N&prime;-substituted biguanides derived from hydroxylamines

Substituted cinnamyl-2,3-dihydrobenzofurans and analogs were prepared from the nucleophlic substitution of a cinnamylhalide with a 2,3-dihydrobenzofuran anion or an analog thereof. These compounds were found to be potent topical anti-inflammatory agents.

Substituted 2-(heteroaryl-2-propenyl)phenols useful as anti-inflammatory

Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as

Hydroxybenzylamino derivatives have been prepared from an appropriate hydroxybenzaldehyde and an amine followed by reduction. These compounds are found to be active topical anti-inflammatory agents.

Hydroxybenzylamino derivatives as anti-inflammatory agents

Substituted 5-hydroxy-2,3-dihydrobenzofuran and analogs such as the substituted 6-hydroxy-2,3-dihydrobenzopyrans were prepared from an appropriately substituted (5-hydroxy-2,3-dihydrobenzofuran-6-yl) formaldehyde or analog thereof with an aryl amine followed by reduction. These compounds were found to be potent topical anti-inflammatory agents.

Substituted 5-hydroxy-2,3-dihydrobenzofurans and analogs thereof useful

Substituted cinnamyl-2,3-dihydrobenzofurans and analogs were prepared from the nucleophilic substitution of a cinnamylhalide with a 2,3-dihydrobenzofuran anion or an analog thereof. These compounds were found to be potent topical anti-inflammatory agents.

The invention relates to 1-[4-(4-sulfanilyl)phenyl] urea and derivatives thereof in pharmaceutical compositions and in methods of treating rheumatoid arthritis and immune complex diseases such as dermatitis herpetiformis.

1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and

Oxazolo[4,5-b]pyridine substituted in the 2-position with a polyhydrobicycloaryl group are topical anti-inflammatory agents. They are prepared by condensing a 2-amino-3-hydroxypyridine with the appropriate carboxylic compound.

2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents

Novel derivatives of 3,6-bis(2-piperidinyl)-2,5-piperazinedione and processes for preparing the same. The new compounds exhibit activity in inhibiting the growth of tumors in mammals and birds, and in inhibiting the growth of certain microorganisms.

3,6-Bis(2-piperidinyl)-2,5-piperazinedione compounds

Stabilized cycloserine compositions, having enhanced stability, and effective in releasing cycloserine compounds in vivo, are prepared by reacting D-4-amino-3-isoxazolidinone or its 5-methyl derivative with 2,4-pentanedione or alkyl-substituted-2,4-pentanedione to form the corresponding N-substituted-cycloserine compound in which one of the hydrogens attached to the primary amino group is replaced by 1-methyl-3-oxo-1-butenyl or an alkyl substituted-1-methyl-3-oxo-1-butenyl grouping. These D-4-(1'-methyl-3'-oxo-1'-butenyl or alkyl-substituted-1'-methyl-3'-oxo-1'-butenyl)amino-3-isoxazolidinones or 5-methyl derivative thereof, which may also be referred to as N-(1-methyl-3-oxo-1-butenyl or alkyl-substituted-1-methyl-3-oxo-1-butenyl)-derivative of cycloserine or methyl-cycloserine, as well as their pharmacologically acceptable salts, are remarkably stable on storage as well as upon oral administration, and are extremely effective in releasing in vivo the cycloserine compound containing the free primary amino grouping.

Growing community of inventors

New Providence, NJ, United States of America

Norman P Jensen